Skip to content
naulon

Not checkedNot checked for notices yet.

Development and evolution of medical technology management in China

Suo-Wei Wu, Qi Pan, Tong Chen and 4 more

Chinese Medical Journal · 2019

doi:10.1097/cm9.0000000000000314 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The National Health Commission of the People's Republic of China (NHC) made a revision on the original version of the Regulation on the Clinical Application of Medical Technology in November 2018.[1] According to the new policy, medical institutions are endowed with the primary responsibility for the management of medical technology. This study aimed to investigate into the development and evolution of policy reform to explore the changes in the concepts and ideas of medical technology management in Chinese medical institutions. The general concept of medical technology can be summarized as measures taken for the purpose of diagnosing and curing diseases, alleviating illnesses, reducing the pain, as well as helping patients restore health and prolonging lives.[2] The clinical application of medical technology discussed in this paper mainly refers to those whose operational processes are proven to be safe and effective in clinical diagnosis or treatment. And the development and evolution on the policies and regulations of medical technology management in China can be mainly divided into four stages: before 2009, 2009–2015, 2015–2018, 2018–present. Before 2009, only a few individual medical technologies (such as the transplantation of hematopoietic stem cells, reproductive assistant technologies and other special technologies) are required for administration.[3] The management on medical technology was isolated and separated, lacking supervision and mainly relied on self-discipline, which lead to disorder in management, as well as the abuse of high-risk technologies involving major ethical issues or hidden dangers (such as limb lengthening technology, cloning technology) that impose threatens on medical safety and resulted in serious social problems. Therefore, the introduction of systematic management policies and regulations on the application of medical technologies was imperative at this stage of time. On this basis, the NHC initiated the Regulation on the Clinical Application of Medical Technology in March 2009, which was China's first political document enacted by the health administration department in systematically regulating the clinical application of medical technology, marking the establishment of the comprehensive management on medical technology in China.[4] The regulation categorized medical technologies into three classes according to their safety and effectiveness. Higher class of medical technologies corresponded to greater risks and difficulties in operation. A classified technological catalog was initiated so that different classes of medical technologies were supervised by varied administrative departments accordingly.[5] In addition, the regulation made clear definitions on the procedures of administration and supervision of medical technology requiring new technologies report to the supervision departments annually within 2 years of admission. The feature of management in this period of time was characterized by the initiation of systematic regulation and supervision.[6] It not only categorized different classes of technology, but also clarified the specific procedure in the whole-rounded-process including the administration, assessment, supervision, and evaluation of medical technology, which was a milestone in the management of medical technology. However, with the implementation of the regulation, problems were gradually emerging. First, the procedures for the approval administration (especially for second and third class technologies) were cumbersome, while the application and suspension of technologies within a medical institution were in dynamic progress.[7] Therefore, the routine procedures added heavy burden to medical institutions and health administrative departments. Even worse, it might lead to regulatory problems. As a result, cases of patients failed to be diagnosed and treated in time which led to seriously medical problems or even caused serious medical accidents due to unreasonable application of medical technology happened frequently (such as the case of Ze-Xi Wei incident, resulted from the abuse of autoimmune cell therapy due to inadequate supervision). Besides, due to the inequality of information between material reporting and practical operation of medical technologies, how to carry out objective assessments became a major problem for health administrative departments.[8] Last but not the least, the time span for mid-term assessment of new technologies lacked flexibility and operability. To be specific, the 2-year assessment period was relatively long for well-developed technologies, while might not be enough for those with higher risks or operational difficulties. Based on above issues, changes in the management pattern were essential, and a revision on the clinical application of medical technologies was carried out for the first time in the year 2015. To simplify the administrative procedures of medical technology management, the 2015 revised edition of Regulation on the Clinical Application of Medical Technology abolished the former approval process of medical technology in administration, and adopted the dynamic recording mechanism instead. Thus, the major responsibility of medical technology management application management was delegated to medical institutions. For the second and third class medical technologies, the health administrative departments were supposed to publicize the information of the technologies in time (such as the list of medical institutions capable of clinical operation and related application materials to the society) for the convenience of public inquiry and supervision. In the revision, the establishment of post-operational supervision mechanism of medical technology was also mentioned.[9] As we look back, the revision of the stage could be regarded as a transitional period for change of perception in medical technology management. The core value of the revolution was to change the approval procedure into recording procedure in admission of new medical technologies, which greatly reduced the cost, improved the efficiency and increased the flexibility in management. Besides, the revised regulation clearly identified that medical institutions were in major charge of medical technology management, which endowed hospitals with greater responsibilities and stricter requirements. Since the new regulation mentioned the establishment of a post-operational supervision mechanism for the clinical application of medical technology and the change of subjects for second and third class medical technology management, the difficulty of management for medical institutions mainly lied in how to carry out specific supervision on these two classes of technology. The absence of explicit definition in specific operational procedures, time interval of supervision in the newly revised regulation might pose risks due to ineffectiveness in management. Through the smooth transition period as well as the continuous improvement of medical technology management in the previous stage, the NHC revised the Regulation on the Clinical Application of Medical Technology for the second time and put into implementation in October 2018. The new regulation was characterized with the complete removal of systematic design for administration approval procedure and the replacement of recording mechanism in the clinical application of new medical technologies. Further, the newly revised version introduced the concept of negative list and restrictive list of medical technologies instead of the former three-classes-technology definition. Moreover, the new regulation made specific requirements on the quality management of medical technology application, the standardization in training and assessment of technical operators, as well as details for public supervision on medical technology, which made further improvement in the whole-rounded-process management system. First, the new regulation introduced negative technology list management mechanism, prohibited the clinical application of forbidden medical technologies, and put more focus on medical technologies that needed stricter supervision. Prohibited technologies were those inaccurate in safety and effectiveness (eg, pituitary alcohol lesion for intractable pain); involving major ethical issues (eg, clonal therapy, surrogate technology); already been clinically eliminated (eg, radial keratotomy) or new technologies that yet to be proved operable in clinical researches (eg, technologies involving the use of drugs, medical devices, preparations that failed to gain the approval of administrative departments), etc. The operation of prohibited technologies was strictly forbidden in clinical. Restrictive technologies were those with relatively greater operational difficulties and risks, in need of scarce resources, involving major ethical issues that called for close attention. The application of prohibited technologies was strictly supervised by provincial or National Health Administrative Departments, and the scope roughly coincided with the second and third class technology compared with the former classification. The core essence in the transformation from three-classes-technology management to negative list management was to adopt compulsory measures in regulating technologies of high-risk, uncertain and ethical, and radically eliminated the application of technologies whose effectiveness and safety could hardly be ensured in clinical practice, which enhanced the strictness in management. Moreover, the new regulation required all medical institutions about to carry out clinical application of restrictive technologies conduct self-assessment according to relevant clinical instrumentations as the basis of operation. Those who met the standards were seen as qualified for conducting further clinical operation. Afterwards, the recording of the technology should be file within 15 days from the date of its first clinical application in l

Abstract licence: CC BY-NC-ND

References5

    5 more references, whose wording the paper’s licence keeps private.

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.